Jan 12 (Reuters) - Drug maker Johnson & Johnson (JNJ.N), opens new tab is exploring a bid to acquire Intra-Cellular Therapies (ITCI.O), opens new tab, a biopharmaceutical company, Bloomberg News ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.

Additionally, the release of a hydroclimate study coincided with the terrible fires in Los Angeles; researchers proposed that cellular coordination ... years old and the core is expected to ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

For two lines in our typical-usage scenario—unlimited on-phone data with 3 GB of mobile-hotspot use—Consumer Cellular is an easy ... now also must present core information about their rate ...

J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...